Hodgkin lymphoma and female fertility: a multicenter study in women treated with ABVD

Author:

Machet Antoine1,Poudou Caroline2,Tomowiak Cécile3,Gastinne Thomas4,Gardembas Martine Micheline5,Systchenko Thomas2,Moya Niels2,Debiais Céline2,Levy Anthony2,Gruchet Cécile2,Sabirou Florence2,Noel Stéphanie2,Bouyer Sabrina1,Leleu Xavier1,Delwail Vincent1,Guidez Stéphanie1ORCID

Affiliation:

1. University Hospital of Poitiers, France

2. CHU Poitiers, Poitiers, France

3. CHU de POITIERS, POITIERS, France

4. University Hospital of Nantes, France

5. Centre Hospitalier de l'Université Angers, Angers, France

Abstract

Preservation of fertility has become a growing concern in young females with Hodgkin lymphoma (HL). However, the rate of pregnancy after the current most frequently prescribed ABVD chemotherapy for HL has rarely been studied. We aimed to determine the impact of ABVD on the fertility of women treated for HL. A non-interventional, multicentric study of female patients of child-bearing age with HL treated. Two healthy apparied women non exposed at chemotherapy (our controls) were assigned for each patient. Fertility was assessed by the number of pregnancies and births after HL treatment. Sixty-seven patients were included. The median age at diagnosis was 24.4 years (16-43). Hodgkin lymphoma was localized disease for 68.7%. 53.7% of all the patients started at least one pregnancy after treatment versus 54.5% of the controls (p=0.92). 81% of patients who desired children had at least one pregnancy. Patients treated with ABVD did not have a longer median time to pregnancy (4.8 years in the group of patients and 6.8 years for controls). Across patients, there has been 58 pregnancies and 48 births (ratio 1.2) and for control cohort, 136 pregnancies and 104 births (ratio 1.3). No increase in obstetric or neonatal complications has been reported in HL in our study. The number of pregnancies, births and the time to start a pregnancy in young women treated with ABVD for HL is not different to that of controls. Therefore, female with HL and treated by ABVD should be reassured in regards to fertility.

Publisher

American Society of Hematology

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3